X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (480) 480
anti-dyskinesia agents - administration & dosage (303) 303
anti-dyskinesia agents - therapeutic use (303) 303
male (266) 266
botulinum toxins - administration & dosage (245) 245
female (240) 240
botulinum toxins - therapeutic use (222) 222
middle aged (175) 175
treatment outcome (170) 170
index medicus (167) 167
botulinum toxin (164) 164
adult (161) 161
clinical neurology (141) 141
aged (117) 117
neurosciences (94) 94
anti-dyskinesia agents - adverse effects (84) 84
animals (81) 81
double-blind (81) 81
anti-dyskinesia agents - pharmacology (75) 75
injections (71) 71
injections, intramuscular (71) 71
botulinum toxins - adverse effects (59) 59
surgery (56) 56
child (54) 54
neurology (52) 52
botulinum toxins - pharmacology (50) 50
muscle spasticity - drug therapy (50) 50
medicine & public health (47) 47
cervical dystonia (46) 46
dystonia (46) 46
psychiatry (46) 46
dose-response relationship, drug (45) 45
time factors (45) 45
gastroenterology & hepatology (44) 44
follow-up studies (43) 43
electromyography (42) 42
pharmacology & pharmacy (42) 42
retrospective studies (42) 42
efficacy (39) 39
aged, 80 and over (37) 37
care and treatment (37) 37
management (37) 37
spasticity (37) 37
adolescent (34) 34
dystonia - drug therapy (33) 33
drug therapy (32) 32
dyskinesia, drug-induced - drug therapy (32) 32
pediatrics (32) 32
prospective studies (31) 31
rats (29) 29
severity of illness index (29) 29
haloperidol (28) 28
otorhinolaryngology (28) 28
rehabilitation (28) 28
safety (28) 28
achalasia (27) 27
torticollis - drug therapy (27) 27
children (26) 26
movement disorders (26) 26
botulinum toxins, type a - administration & dosage (25) 25
botulinum toxins, type a - therapeutic use (25) 25
injection (25) 25
injections, intralesional (25) 25
a toxin (24) 24
disease models, animal (24) 24
research (24) 24
therapy (24) 24
blepharospasm - drug therapy (23) 23
child, preschool (23) 23
dosage and administration (23) 23
parkinsons-disease (23) 23
placebo-controlled trial (23) 23
drug administration schedule (22) 22
esophageal achalasia - drug therapy (22) 22
esophageal achalasia - therapy (22) 22
parkinson's disease (22) 22
botulinum toxins (20) 20
haloperidol - therapeutic use (20) 20
health aspects (20) 20
muscle spasticity - etiology (20) 20
pain (20) 20
trial (20) 20
anti-dyskinesia agents (19) 19
cerebral palsy (19) 19
cerebral palsy - drug therapy (19) 19
cerebral-palsy (18) 18
clinical trials as topic (18) 18
double-blind method (18) 18
ophthalmology (18) 18
rats, wistar (18) 18
disorders (17) 17
haloperidol - administration & dosage (17) 17
parkinson disease - drug therapy (17) 17
tardive dyskinesia (17) 17
antipsychotic agents - adverse effects (16) 16
drug therapy, combination (16) 16
hemifacial spasm (16) 16
injections, intramuscular - methods (16) 16
magnetic resonance imaging (16) 16
manometry (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (485) 485
French (17) 17
German (11) 11
Japanese (10) 10
Spanish (8) 8
Russian (5) 5
Finnish (1) 1
Norwegian (1) 1
Romanian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drugs, ISSN 0012-6667, 2015, Volume 75, Issue 5, pp. 487 - 501
... delivery over 24 h, with a plasma concentration profile similar to that of administration via continuous intravenous infusion... 
PLASMA-LEVELS | SAFETY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OPEN-LABEL | TOXICOLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | CLINICAL-FEATURES | LONG-TERM TREATMENT | PATCH | AGONIST N-0437 | Thiophenes - therapeutic use | Restless Legs Syndrome - epidemiology | Thiophenes - adverse effects | Humans | Dopamine Agonists - therapeutic use | Tetrahydronaphthalenes - therapeutic use | Dopamine Agonists - adverse effects | Parkinson Disease - drug therapy | Thiophenes - administration & dosage | Tetrahydronaphthalenes - adverse effects | Restless Legs Syndrome - metabolism | Antiparkinson Agents - therapeutic use | Restless Legs Syndrome - drug therapy | Drug Interactions | Tetrahydronaphthalenes - administration & dosage | Parkinson Disease - epidemiology | Anti-Dyskinesia Agents - administration & dosage | Parkinson Disease - metabolism | Comorbidity | Dopamine Agonists - pharmacokinetics | Tetrahydronaphthalenes - pharmacokinetics | Evidence-Based Medicine | Antiparkinson Agents - adverse effects | Transdermal Patch - adverse effects | Antiparkinson Agents - pharmacokinetics | Anti-Dyskinesia Agents - therapeutic use | Thiophenes - pharmacokinetics | Animals | Anti-Dyskinesia Agents - adverse effects | Dopamine Agonists - administration & dosage | Antiparkinson Agents - administration & dosage | Anti-Dyskinesia Agents - pharmacokinetics | Practice Guidelines as Topic
Journal Article
Journal Article
Psychopharmacology, ISSN 0033-3158, 10/2006, Volume 188, Issue 3, pp. 281 - 292
This double-blind, placebo-controlled study investigated the efficacy and safety of intramuscular (IM) aripiprazole and IM haloperidol for the treatment of... 
Intramuscular antipsychotic therapy | Acute agitation | Efficacy | Intramuscular aripiprazole | Safety | Intramuscular haloperidol | intramuscular aripiprazole | MANAGEMENT | PSYCHIATRY | NEUROSCIENCES | acute agitation | efficacy | ATYPICAL ANTIPSYCHOTICS | RELAPSE | safety | intramuscular antipsychotic therapy | PHARMACOLOGY & PHARMACY | OLANZAPINE | SHORT-TERM | ZIPRASIDONE | Piperazines - administration & dosage | Psychotic Disorders - complications | Antipsychotic Agents - adverse effects | Humans | Haloperidol - administration & dosage | Male | Schizophrenia - complications | Withholding Treatment - statistics & numerical data | Aripiprazole | Psychomotor Agitation - drug therapy | Quinolones - adverse effects | Time Factors | Antipsychotic Agents - therapeutic use | Quinolones - therapeutic use | Adult | Female | Anti-Dyskinesia Agents - administration & dosage | Drug Therapy, Combination | Basal Ganglia Diseases - chemically induced | Acute Disease | Double-Blind Method | Administration, Oral | Haloperidol - therapeutic use | Treatment Outcome | Piperazines - therapeutic use | Injections, Intramuscular | Haloperidol - adverse effects | Piperazines - adverse effects | Antipsychotic Agents - administration & dosage | Anti-Dyskinesia Agents - therapeutic use | Quinolones - administration & dosage | Anti-Dyskinesia Agents - adverse effects | Adolescent | Psychomotor Agitation - complications | Benzodiazepines - administration & dosage | Benzodiazepines - adverse effects | Psychotic Disorders - drug therapy | Schizophrenia - drug therapy | Blood Glucose - metabolism | Benzodiazepines - therapeutic use | Schizophrenia | Clinical trials | Comparative studies | Side effects | Pharmacology | Muscular system
Journal Article
Neurobiology of Disease, ISSN 0969-9961, 2016, Volume 94, pp. 179 - 195
... ' s disease (PD), at least in the first and middle phases of the disorder ( Carlsson, 2002; Connolly and Lang, 2014 ). However, L-DOPA administration only ameliorates... 
Neurology | AIMs | NF-κB | CB1 | COX-2 | pAcH3 | LID | TRPV-1 | Neuroinflammation | ERK 1/2 | Cannabinoid | PPAR gamma | Anandamide | NITRIC-OXIDE SYNTHASE | PROLIFERATOR-ACTIVATED RECEPTORS | GAMMA PPAR-GAMMA | ABNORMAL INVOLUNTARY MOVEMENTS | NEUROSCIENCES | MESSENGER-RNA LEVELS | RAT MODEL | NF-kappa B | LEVODOPA-INDUCED DYSKINESIA | NF-KAPPA-B | CANNABINOID RECEPTOR AGONIST | PARKINSONS-DISEASE | Endocannabinoids - metabolism | Tyrosine 3-Monooxygenase - metabolism | Dyskinesia, Drug-Induced - physiopathology | Anti-Dyskinesia Agents - toxicity | Capsaicin - pharmacology | Male | NF-kappa B - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Oxidopamine | PPAR gamma - metabolism | TRPV Cation Channels - metabolism | Arachidonic Acids - metabolism | Dyskinesia, Drug-Induced - drug therapy | Parkinsonian Disorders - drug therapy | Parkinsonian Disorders - physiopathology | Mice, Inbred C57BL | Cannabidiol - pharmacology | Capsaicin - analogs & derivatives | Levodopa - toxicity | Dyskinesia, Drug-Induced - pathology | Polyunsaturated Alkamides - metabolism | Brain - drug effects | Receptor, Cannabinoid, CB1 - metabolism | Anti-Dyskinesia Agents - pharmacology | Animals | Parkinsonian Disorders - pathology | Cyclooxygenase 2 - metabolism | Brain - pathology | Histones - metabolism | Physiological aspects | Phenols | COX-2 inhibitors | Fatty acids | Movement disorders
Journal Article
Neuroscience, ISSN 0306-4522, 2017, Volume 357, pp. 84 - 98
Highlights • M1 receptor expression is increased in the dorsomedial striatum of dtsz hamsters. • M2/M4 receptor binding is altered in limbic structures of dtsz... 
Neurology | muscarinic | basal ganglia | acetylcholine | movement disorders | striatum | PRIMARY PAROXYSMAL DYSTONIA | PARVALBUMIN-POSITIVE INTERNEURONS | PROJECTION NEURONS | SUBTYPE-SPECIFIC ANTIBODIES | NEUROSCIENCES | MUTANT HAMSTERS | disorders | AGE-RELATED-CHANGES | GABAERGIC INTERNEURONS | STRIATAL CHOLINERGIC INTERNEURONS | ANIMAL-MODEL | movement | RODENT MODEL | Limbic System - pathology | Dystonia - pathology | Male | Receptor, Muscarinic M1 - antagonists & inhibitors | Dystonia - metabolism | Limbic System - metabolism | Thiophenes - administration & dosage | Corpus Striatum - metabolism | Dose-Response Relationship, Drug | Mesocricetus | Female | Anti-Dyskinesia Agents - administration & dosage | Drug Therapy, Combination | Corpus Striatum - pathology | Disease Models, Animal | Limbic System - drug effects | Severity of Illness Index | Pyridines - administration & dosage | Receptor, Muscarinic M4 - metabolism | Dystonia - drug therapy | Disease Progression | Muscarinic Antagonists - administration & dosage | Animals | Corpus Striatum - drug effects | Tropicamide - administration & dosage | Mutation | Receptor, Muscarinic M4 - antagonists & inhibitors | Trihexyphenidyl - administration & dosage | Receptor, Muscarinic M1 - metabolism | Hamsters | Analysis | Parasympatholytic agents | Movement disorders | Index Medicus
Journal Article
Neurotherapeutics, ISSN 1933-7213, 7/2018, Volume 15, Issue 3, pp. 715 - 727
.... Pimozide, a Food and Drug Administration (FDA)-approved neuroepileptic drug, has been recently proposed as a promising treatment for ALS patients based on apparent stabilization of right hand muscles after a short-time administration... 
Neurology | Neurosciences | Biomedicine | TDP-43 | Neurobiology | ALS | Pimozide | Neurosurgery | SOD1 | CHAKRAGATI MOUSE | AUTOPHAGY | NEUROSCIENCES | CLINICAL NEUROLOGY | CHILDREN | SCLEROSIS/FRONTOTEMPORAL LOBAR DEGENERATION | TREMOR | INHIBITION | PHARMACOLOGY & PHARMACY | PROTEINS | BRAIN | Superoxide Dismutase - genetics | Muscle Strength - genetics | Age Factors | Neuromuscular Junction - drug effects | Humans | Body Weight - drug effects | Motor Activity - drug effects | Male | Phosphopyruvate Hydratase - metabolism | Neuromuscular Agents - therapeutic use | Body Weight - genetics | DNA-Binding Proteins - metabolism | Botulinum Toxins, Type A - therapeutic use | Statistics, Nonparametric | Female | Anti-Dyskinesia Agents - administration & dosage | Neuromuscular Junction - pathology | Superoxide Dismutase - metabolism | Disease Models, Animal | Pimozide - adverse effects | Amyotrophic Lateral Sclerosis - genetics | Mice, Transgenic | DNA-Binding Proteins - genetics | Mutation - genetics | Amyotrophic Lateral Sclerosis - complications | Motor Activity - genetics | Amyotrophic Lateral Sclerosis - pathology | Animals | Movement Disorders - etiology | Mice | Muscle Strength - drug effects | Movement Disorders - drug therapy | Animal models | Innervation | Transgenic mice | Muscles | Clinical trials | Amyotrophic lateral sclerosis | Superoxide dismutase | Superoxide | Drug delivery | Patients | DNA-binding protein | Rodents | Neuromuscular junctions | Mutation | Original
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 10/2012, Volume 83, Issue 10, pp. 1012 - 1014
Journal Article
Journal Article